SKBA Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-12,820
Closed -$302K 80
2018
Q3
$302K Sell
12,820
-423,700
-97% -$10.3M 0.04% 70
2018
Q2
$10.1M Sell
436,520
-7,400
-2% -$176K 1.36% 41
2018
Q1
$10.9M Sell
443,920
-102,600
-19% -$2.69M 1.48% 34
2017
Q4
$14.7M Sell
546,520
-8,600
-2% -$219K 2.04% 20
2017
Q3
$13.4M Buy
555,120
+48,400
+10% +$1.09M 1.92% 28
2017
Q2
$10.9M Buy
506,720
+41,200
+9% +$831K 1.64% 29
2017
Q1
$7.98M Buy
+465,520
New +$8.11M 1.06% 40

Other funds holding NVO

SKBA Capital Management's NVO Position: Q4 2018 in Review

SKBA Capital Management sold out of Novo Nordisk (NVO) in Q4 2018, closing a stake of 12,820 shares — an estimated $302K sold.

SKBA Capital Management first reported a position in NVO in Q1 2017 and held it in 7 quarters. The position peaked at $14.7M in Q4 2017. 550 funds tracked by Wall St. Rank hold NVO as of Q4 2018.

  • SKBA Capital Management reported no remaining Novo Nordisk position as of Q4 2018 after selling out during the quarter.
  • SKBA Capital Management sold 12,820 Novo Nordisk shares in Q4 2018, an estimated $302K.
  • SKBA Capital Management first reported a position in Novo Nordisk in Q1 2017 and held it in 7 quarters.
  • SKBA Capital Management's Novo Nordisk position peaked at $14.7M in Q4 2017.
  • 550 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2018.

Based on SKBA Capital Management's 13F filing for Q4 2018, filed 7 Feb 2019.